Appendix 4 (as submitted by the authors): Cost-Effectiveness Results for different age ranges							
		Compare to Common baseline (No Screening)					
Age Range	Strategy	Cost	QALYs	ΔCost	ΔQALYs	ICER	Sequential ICER
25-44	No screening	$58,120	15.5938	-	-	-	
	Screen & treat with PR	$58,225	15.5961	$105	0.0023	$45,424	$45,424*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	$58,307	15.5994	$187	0.0056	$33,331	$33,331
	Screen & treat with G1: simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	$58,309	15.5985	$189	0.0048	$39,514	Dominated
25-54	No screening	$65,538	14.6690	-	-	-	
	Screen & treat with PR	$65,660	14.6721	$122	0.0031	$39,175	$39,175*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	$65,783	14.6764	$245	0.0074	$33,015	$33,015
	Screen & treat with G1: simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	$65,784	14.6751	$246	0.0062	$39,942	Dominated
25-64	No screening	$71,327	13.7653	-	-	-	
	Screen & treat with PR	$71,450	13.7685	$124	0.0032	$38,117	$38,117*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	$71,593	13.7729	$266	0.0077	$34,783	$34,783
	Screen & treat with G1: simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	$71,593	13.7716	$267	0.0063	$42,398	Dominated

Wong WWL, Tu HA, Feld JJ, et al. Cost-effectiveness of screening for hepatitis C in Canada. *CMAJ* 2015. DOI:10.1503/cmaj.130711.
Copyright © 2015 The Author(s) or their employer(s).
To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca

		Compare to Common baseline (No Screening)					
Age Range	**Strategy**	**Cost**	**QALYs**	**ΔCost**	**ΔQALYs**	**ICER**	**Sequential ICER**
35-54	No screening	$71,324	13.9585	-	-	-	-
	Screen & treat with PR	$71,453	13.9620	$128	0.0035	$37,140	$37,140*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	$71,595	13.9667	$271	0.0082	$33,210	$33,210
	Screen & treat with G1: simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	$71,596	13.9652	$272	0.0067	$40,507	Dominated
35-64	No screening	$77,099	12.9974	-	-	-	
	Screen & treat with PR	$77,227	13.0009	$128	0.0035	$36,517	$36,517*
	Screen & treat with G1:simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	$77,389	13.0041	$290	0.0067	$43,345	$43,345*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	$77,390	13.0057	$291	0.0082	$35,296	$35,296
45-64	No screening	$83,335	12.1027	-	-	-	-
	Screen & treat with PR	$83,476	12.1068	$141	0.0041	$34,359	$34,359
	Screen & treat with G1:simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	$83,672	12.1104	$337	0.0077	$44,034	$55,151*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	$83,673	12.1122	$338	0.0095	$35,562	$36,471

G1: genotype 1; G2/3: genotype 2 or 3; G4/5/6: genotype 4 or 5 or 6; PR = pegylated interferon plus ribavirin; QALY = quality-adjusted life-year; SIM = simeprevir; SOF/RBV = sofosbuvir plus ribavirin; IFN-Free DAA = interferon=free direct-acting antiviral agents; ICER = incremental cost-effectiveness ratio

[a]Extendedly dominated = the combination of two other alternatives dominated the treatment.



Effect of age of those screened on incremental cost-effectiveness ratio (ICER). PR = pegylated interferon plus ribavirin, QALY = quality-adjusted life-year, IFN-free DAA = interferon-free direct-acting antiviral therapy.